Vécsei, László

The epidemiology of multiple sclerosis in Europe

Pugliatti, M., Rosati, G., Carton, H., Riise, T., Drulovic, J., Vécsei, L., & Milanov, I. (2006) · European Journal of Neurology

Multiple Sclerosis Research StudiesHealth Systems, Economic Evaluations, Quality of Life

Cited by 654

Kynurenines in the CNS: recent advances and new questions

Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery

Tryptophan and brain disordersMigraine and Headache Studies

Cited by 641

Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study

Kuhle, J., Disanto, G., Dobson, R., Adiutori, R., Bianchi, L., Topping, J., Bestwick, J., Meier, U.-C., Marta, M., Costa, G. D., et al. (2015) · Multiple Sclerosis Journal

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 299

Neurofilament ELISA validation

Petzold, A., Altintas, A., Andreoni, L., Bartos, A., Berthele, A., Blankenstein, M. A., Buee, L., Castellazzi, M., Cepok, S., Comabella, M., et al. (2010) · Journal of Immunological Methods

Clinical Laboratory Practices and Quality ControlReliability and Agreement in Measurement

Cited by 105

Kynurenic Acid and Its Synthetic Derivatives Protect Against Sepsis-Associated Neutrophil Activation and Brain Mitochondrial Dysfunction in Rats

Poles, M. Z., Nászai, A., Gulácsi, L., Czakó, B. L., Gál, K. G., Glenz, R. J., Dookhun, D., Rutai, A., Tallósy, S. P., Szabó, A., et al. (2021) · Frontiers in Immunology

Tryptophan and brain disordersSepsis Diagnosis and Treatment

Cited by 49

Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design

Tanaka, M., Szatmári, I., & Vécsei, L. (2025) · Pharmaceuticals

Tryptophan and brain disordersComputational Drug Discovery Methods

Cited by 30

From Microbial Switches to Metabolic Sensors: Rewiring the Gut–Brain Kynurenine Circuit

Tanaka, M., & Vécsei, L. (2025) · Biomedicines

Tryptophan and brain disordersGut microbiota and health

Cited by 24

The effects of bilateral theta-burst stimulation on executive functions and affective symptoms in major depressive disorder

Holczer, A., Németh, V. L., Vékony, T., Kocsis, K., Király, A., Kincses, Z. T., Vécsei, L., Klivényi, P., & Must, A. (2021) · Neuroscience

Transcranial Magnetic Stimulation StudiesTreatment of Major Depression

Cited by 15

The Power Struggle: Kynurenine Pathway Enzyme Knockouts and Brain Mitochondrial Respiration

Juhász, L., Spisák, K., Szolnoki, B. Z., Nászai, A., Szabó, Á., Rutai, A., Tallósy, S. P., Szabó, A., Toldi, J., Tanaka, M., et al. (2025) · Journal of Neurochemistry

Tryptophan and brain disordersMitochondrial Function and Pathology

Cited by 15

Decoupling Neuroprotection and Motor Dysfunction via Kynurenic Acid Analog Optimization: Implications for Schizophrenia and Parkinson’s Disease Therapeutics

Martos, D., Lőrinczi, B., Szatmári, I., Vécsei, L., & Tanaka, M. (2025) · Cells

Tryptophan and brain disordersSchizophrenia research and treatment

Cited by 13

Promising therapeutic agents for the treatment of Parkinson’s disease

Majláth, Z., Török, N., Toldi, J., & Vécsei, L. (2016) · Expert Opinion on Biological Therapy

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 7

Receptor–Mitochondria Crosstalk in the Kynurenine Metabolic Pathway: Integrating Metabolomics and Clinical Mass Spectrometry

Juhász, L., Galla, Z., Tanaka, M., & Vécsei, L. (2026) · Antioxidants

Tryptophan and brain disordersSirtuins and Resveratrol in Medicine

Cited by 5